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Background: Responsiveness to clopidogrel has been reported to be related with MACE after coronary stenting with DES. Additionally, because of 
the known CYP3A4 inhibition by calcium-channel blockers (CCBs), there might be a drug-drug interaction between clopidogrel and CCBs in patients 
with DES. We sought to assess whether the low response to clopidogrel and co-administration of CCB after stenting influences the clinical outcomes 
after coronary stenting with DES in a consecutively measured cohort of Korean patients.
Methods: 210 patients with stable angina (n=104) and acute coronary syndrome (ACS) (n=106) undergoing percutaneous coronary stenting were 
enrolled in this study. Patients were assigned to clopidogrel low responder (group A) and responder group (group B). Enrolled patients underwent 
consecutive 12 and 24-months angiographic follow-up and other clinical events were observed upto 36 months. Major adverse cardiac events 
(MACEs) were defined as cardiac death, acute myocardial infarction, in stent restenosis (ISR), and target lesion revascularization (TLR). ISR was 
defined as 50% diameter stenosis occurring in the segment inside the stent.
Results: 86 (40.9%) patients were clopidogrel low responder. In comparing with stable angina and ACS group, there was no significant difference 
in prevalence of clopidogrel resistance (44.2% in stable angina versus 37.7% in ACS, p=NS). Group A showed a significantly higher risk of ISR and 
target lesion revascularization (20.9% vs. 1.6%, p<0.01) compared with group B, though there was difference in all cause MACEs in both groups 
during 36 months follow-up. In sub-analysis, treatment with calcium channel blockers (CCBs) after coronary stenting was significantly correlated with 
all cause MACEs in regression analysis (p<0.05).
Conclusions: Clopidogrel low responder treated by stenting can be considered as one of the risk factors of ISR in DES era. Besides, co-
administration of CCBs associated with increased all cause MACE after stenting may be due to decreased platelet inhibition by clopidogrel. Co-
administration of CCBs with clopidogrel after DES implantation should be done cautiously, especially in low clopidogrel responder group.
